Hangzhou Biotest Soars 6.15%, Hits Intraday High of CNY 40.30

Hangzhou Biotest Biotech Co., Ltd. has experienced a notable increase of 6.15% on May 22, 2026, reaching an intraday high of CNY 40.30. This performance stands in contrast to the China Shanghai Composite, which rose by only 0.87% on the same day. Despite this positive movement, the company has faced challenges in its longer-term performance metrics. Over the past year, Hangzhou Biotest has seen a decline of 11.02%, while the broader market has gained 21.68%. The company's year-to-date performance is slightly better at 5.98%, outpacing the Shanghai Composite's 3.63%. Financially, Hangzhou Biotest's net sales have contracted at an annual rate of -38.86% over the last five years, and its operating profit has decreased by 63.30%. The latest quarterly net profit reported was CNY 9.86 million, reflecting a significant drop of 42.12%. The company's debt-equity ratio stands at -0.59, indicating a challenging financial position. Overall, while today's activity marks a high point, the underlying financial metrics suggest a complex landscape for Hangzhou Biotest Biotech Co.